Growth Hormone's Effect on Endothelial Progenitor Cells

Completed · Not applicable

Conditions studied: Cardiovascular Disease

In brief

To assess the effect of short-term low-dose growth hormone therapy on the mobilization of endothelial progenitor cells from the bone marrow within a group of healthy adults.

Key facts

Study ID

NCT00397592

Run by

Vanderbilt University

People needed

18

Starts

2006-08-01

Expected to finish

2007-01-01

Last updated by the study team

2007-07-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults age 18 thru 65
• Serum IGF-1 in the lower half of the age and gender-specific normal range at the time of screening visit

You may not qualify if…

• Systemic hypertension, as defined as current BP >140/90 on screening visit, or taking anti-hypertensive therapy.
• Diabetes mellitus, as defined by known diagnosis or Fasting Blood Glucose >126 at the time of screening visit.
• Women who are pregnant or nursing, as confirmed by history or seum beta-hCG at the time of screening visit.
• Women who are taking exogenous oral estrogens of any kind.
• Personal history of active cancer or recurrence within the past 10 years, with the exception of non-melanoma skin cancer.
• Personal history of an untreated benign intracranial neoplasm.
• Initiation of statin therapy during the course of the study.
• A serum IGF-1 level below the age and gender-specific normal range at the time of screening visit.
• Renal insufficiency, as defined by a GFR <60 mls/min/1.73 m2 upon Renal Function panel at the time of screening visit.
• Hepatic insufficiency, as defined by an AST and/or ALT >twice the upper limit of normal at the time of screening visit.

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.